RNA modification writer expression profiles predict clinical outcomes and guide neoadjuvant immunotherapy in non-small cell lung cancer
Author:
Publisher
Elsevier BV
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference47 articles.
1. Lung cancer: current therapies and new targeted treatments;Hirsch;Lancet,2017
2. Worldwide burden and epidemiological trends of tracheal, bronchus, and lung cancer: a population-based study;Zhou;EBioMedicine,2022
3. Targeting the complement pathway as a therapeutic strategy in lung cancer;Kleczko;Front Immunol,2019
4. Role of RNA modifications in cancer;Barbieri;Nat Rev Cancer,2020
5. Epigenetic N6-methyladenosine modification of RNA and DNA regulates cancer;Liang;Cancer Biol Med,2020
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Five-year follow-up of neoadjuvant PD-1 inhibitor (sintilimab) in non-small cell lung cancer;Journal for ImmunoTherapy of Cancer;2024-08
2. The role of RNA methylation in tumor immunity and its potential in immunotherapy;Molecular Cancer;2024-06-20
3. Role of m6A modifications in immune evasion and immunotherapy;Medical Oncology;2024-05-18
4. Abnormal changes in metabolites caused by m6A methylation modification: The leading factors that induce the formation of immunosuppressive tumor microenvironment and their promising potential for clinical application;Journal of Advanced Research;2024-04
5. Genomic characteristics and immune landscape of super multiple primary lung cancer;eBioMedicine;2024-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3